, 852 severely head-injured patients were entered into a prospective placebo-controlled trial of the efficacy of nimodipine administration. The patients could not obey commands at the time of entry into the trial, which was within 12 hours after the start of the inability to obey commands and within 24 hours of injury. The main hypothesis that nimodipine would increase the percentage of patients with a favorable outcome (moderate disability or good recovery) from 50% to 60% was rejected.
v
ARIOUS types of delayed insult can lead to secondary brain damage after a head injury, but in many cases the pathway leading to brain damage is a critical reduction in cerebral blood flow (CBF) or oxygenation, resulting in hypoxic/ischemic brain damage. 13,2L31 Calcium antagonists reduce brain damage in experimental models of cerebral ischemia and hemorrhage,lO.~ 1,I6,i7,22.23,32-35 and also decrease rates of mortality and morbidity due to delayed ischemic deterioration after subarachnoid hemorrhage (SAH). L9, 14, 18, 19, [23] [24] [25] [26] 36 The benefits of calcium antagonists stimulated a group of British and Finnish clinicians to carry out a randomized prospective placebo-controlled clinical trial of the effect of nimodipine administration on outcome in 350 patients with a severe head injury. 2 This head injury trial (HIT 1) showed that, while it was unlikely that nimodipine had a marked effect upon outcome, a modest but nevertheless clinically valuable benefit was possible. It was therefore necessary to carry out a further trial involving a larger number of subjects.
We report the results of a prospective and randomized double-blind placebo-controlled trial (HIT 2) involving over 800 severely head-injured patients. The aim of the study was to establish whether nimodipine increased the percentage of patients with a favorable outcome (moderate disability or good recovery) by 10% at 6 months after a severe head injury. Secondary endpoints were mortality and the classification of survivors into four subgroups of outcome.
Clinical Material and Methods

Patient Selection
The trial was performed between January 1, 1989, and December 31, 1991, in 21 centers located in 13 European countries.* Patients were eligible if: 1) they were aged between 16 and 70 years; 2) they could not obey commands at the time of assessment for entry into the trial; and 3) they had undergone computerized tomography (CT). Most patients were not able to obey commands from the time of the injury, but some patients initially obeyed commands and deteriorated later. In order to include both groups of patients, an additional entry criterion was the initiation of treatment with the test drug within 24 hours after injury and within 12 hours of the patient not obeying commands. Each patient had to be in a stable systemic condition at the commencement of administration of the test drug.
Patients were excluded if any one of the following criteria was fulfilled: 1) responsiveness could not be assessed due to the effects of previous treatment, such as sedation, paralysis, and ventilation; 2) injury was due to a gunshot wound; 3) the patient was in an unstable systemic condition; 4) the patient was pregnant; 5) wide nonreacting pupils were present and motor response was absent for more than 2 hours; 6) death was thought likely to occur within the next 24 hours as a result of severe multiple injuries; and 7) it was considered unlikely that the patient would be available for follow-up evaluation at 6 months.
The purpose of the study, the protocol, and the procedure for obtaining consent were approved by the Ethics Committee of each participating center. For most patients, consent for entry was obtained from a relative and recorded in writing. In cases where the relative could not be contacted, the patient was entered into the study and treatment either continued until subsequent approval was obtained or, if consent was not forthcoming, was stopped after 48 hours and the patient was withdrawn from the study.
Study Design
The determination of sample size was based upon the expectation that in the chosen patient population, about 50% would have a favorable outcome. This meant that a minimum of 376 patients were required in each of the two study groups (nimodipine vs. placebo) in order for the trial to have an 80% chance (with a significance level of 0.05) of detecting an increase in favorable outcome from 50% to 60%.
Patients were randomly assigned to the two treatment groups using a separate randomization for each center. These were balanced in blocks of four. All patients, relatives, and personnel in each participating center and those responsible for the analysis were blinded to the treatment coding. The investigator in each center was supplied with a sealed envelope containing the randomization code of each individual patient. These were not to be opened unless it was considered absolutely necessary, namely to manage a serious adverse event. However, even in these circumstances, treatment could be discontinued without breaking the code. A record was maintained of all patients eligible for entry into the study but who, for whatever reason, were not recruited.
Test Drug Administration
The test drug (nimodipine or placebo) was administered in an intravenous infusion through a central or peripheral line from bottles shielded from direct sunlight. The treatment was infused constantly, in a bypass with other infusion fluids. The test drug was initially given at a dose of 1 mg/hr; this was increased after 2 hours to 2 mg/hr provided there was no adverse response, such as hypotension. Treatment was continued for 7 days or until the death of the patient. Trial compliance was monitored and was considered to be satisfactory if the patient received more than 80% of the appropriate total dose. Treatment could be stopped at the request of a patient or relative, or if the clinician in charge of the patient considered that treatment was having adverse effects. 
Clinical and Radiological Examination
The initial clinical observations recorded were those made when the patient first arrived at the hospital. Subsequent recordings included the findings on admission to the neurosurgical unit, at the time of entry into the trial, and during the first 7 days after starting treatment. The data recorded were level of consciousness (using the Glasgow Coma Scale), reactivity of the pupils to light, and motor pattern as judged from limb strength and symmetry of movement. Also recorded were the age of the patient, cause of injury, clinical course since injury, blood pressure, and clinical or radiographic evidence of a skull fracture.
Computerized tomography was performed on all patients prior to entry into the trial. The presence of an epidural, subdural, or intracerebral hematoma was noted, as were the presence of contusions with or without a mass effect, the extent of midline shift, and the presence of signs of elevated intracranial pressure (ICP) such as obliteration of the basal cisterns and the third ventricle. Evidence of SAH on CT scans received particular attention. Blood and urine samples obtained on admission and on the 1st, 3rd, and 7th days of the hospital stay were tested for possible deviation of values (from reference values) due to the nimodipine treatment. Potential adverse reactions, particularly those affecting blood pressure and the cardiovascular system, 17,28 were recorded.
Data Collection
Each case report form was checked during regular visits against the original case report and laboratory results by an experienced trial monitor. All queries and implausibilities were discussed with the investigator. Checks were also performed by the Biometric Department of Bayer Pharmaceutical Research Centre, Wuppertal, Germany.
The case report forms for each patient were sent to the Central Data Office in Wuppertal and again reviewed by a committee composed of three neurosurgeons. Implausibilities were investigated and all CT scans reassessed, but a change in the data reported was made only after close consultation with and with the agreement of the investigator. An analysis was also carried out for the assessment of SAH by the review committee.
Clinical Treatment
Patients were treated according to general neurosurgical standards as applied in the different centers. Decisions about aspects of treatment such as whether lCP should be monitored, the patient should be artificially ventilated, or an intracranial hematoma should be evacuated were made by the surgeon in charge of the patient, unrelated to the conduct of the study. The concurrent use of calcium antagonists and megadoses of steroids (equivalent to > 100 mg/day of dexamethasone) was not allowed, nor was the use of deep barbiturate-induced coma, except as a last resort.
Outcome
The Glasgow Outcome Scale (GOS) 15 was used to classify the patients' condition at 6 months. Moderate disability or good recovery was considered to represent a favorable outcome; death, persistent vegetative state, or severe disability was regarded as an unfavorable outcome. Outcome was assessed by a personal interview between the local investigators and the patient and/or a relative at an interval of 5~ to 6 89 months after entry into the trial.
An assessment of different aspects of function was performed as an aid to interpretation and validation of the outcome classified by the GOS. These features were: memory, cognitive function, speech disorder, paresis, personality, social integration, epilepsy, and return to work. None of these items was used as an independent endpoint. Outcome data also received close scrutiny by the review committee.
Statistical Analysis
The primary statistical analysis followed the "intention to treat" principle. The only reason that patients were excluded from the analysis was lack of information about their outcome. The primary comparison was between the proportion of patients in each group who achieved a favorable outcome, and was made using frequency tables. Furthermore, as specified in the protocol, logistic regression was incorporated in the primary analysis, with patient age, sex, whether craniotomy was performed, pupillary reactions, and motor responses as covariates. However, because many patients were ventilated at the time of entry into the study, data on con- sciousness level were often missing. The results of the logistic regression were presented as "weighted odds ratio," which includes a "mean odds ratio" and 95% confidence intervals (equivalent to significance tests, but more appropriate for comparisons of this nature). A life table analysis was included to compare the survival rates.
A secondary explanatory analysis was performed on "valid patients," defined as the patients who fulfilled all enrollment criteria, complied with treatment, and had adequate assessment of outcome. The principal reason for a patient being regarded as "invalid" was lack of compliance with the study protocol, namely, the administration of less than 80% of the test drug during a specified period.
Disability following a head injury may, in addition to the effects of brain damage, be due to extracranial injuries, such as a spinal cord injury or an amputated leg. Outcome due to brain damage was therefore assessed separately for the primary analysis on the intention-to-treat basis and for the valid cases.
Results
Between January 1, 1989, and June 30, 1991, 852 patients were enrolled in the trial; 423 received nimodipine and 429 received placebo (Table 1 ). The demographic features of the two groups were not statistically different ( Table 2 ). The interval between injury and the time of entry into the trial is also presented in response and pupillary reaction at the time of entry into the trial are presented in Table 4 . A craniotomy to evacuate a hematoma or other mass lesion was performed in 314 cases. In 222 cases this was carried out before the patient was entered into the study. Operations for extracranial injuries or other complications of a head injury were performed on 37 of the patients receiving nimodipine and 48 of those receiving placebo.
Of the 819 patients for whom outcome data were available and who, therefore, could be included in the intention-to-treat analysis, 165 (20%) were later determined to be invalid for various reasons. A total of 654 valid patients remained for secondary explanatory analysis (Table 1) . During the period of the trial, 233 patients in 17 centers were potentially eligible for study but were not recruited.
Outcome
The outcomes in the 819 patients with data available at 6 months after injury are shown in Table 5 . The outcome was favorable in 245 (60.5%) of the patients given nimodipine and in 246 (59.4%) of the patients receiving placebo (difference not significant). There was a wider difference in outcome between the two groups of valid cases; a favorable outcome occurred in 60.7% of those given nimodipine and in 57.0% of those given placebo ( Table 6 ).
The overall outcome differed from that considered to be due to brain damage in only 22 patients. Eleven of these had received nimodipine and 11 placebo. Outcome due to brain damage did not differ in nimodipineor placebo-treated patients (favorable outcome: 61.7% vs. 57.5%). Similarly, death was considered to be a direct effect of the damage to the brain in 88% of those who died in the placebo group and in 82% of those in the nimodipine group.
Analysis of the different components of functional outcome did not reveal major differences between the two groups. In addition, there was no statistical difference in the survival curve for the two groups (Fig, 1) . No statistically significant difference in outcome was seen between both treatment groups, irrespective of the interval between injury and start of treatment (Table  7) . No major differences between the outcomes in the nimodipine-or placebo-treated patients were observed in a number of other subgroups, except in the subgroup in which the initial CT scan showed SAH (Table 8) . Nimodipine treatment was associated with a trend toward improved outcome, indicated by a statistically significant improvement in the valid cases. This trend was apparent both when the diagnosis of SAH was based upon the observation of the investigator and when the judgments were made by the review committee.
lntracranial Pressure
Intracranial pressure monitoring was performed in about 41% of all patients; measurements were more frequent within the first 3 days after entry into the trial. One-third of the patients with ICP monitoring had at least one daily value in excess of 20 mm Hg. Placebotreated patients had a slightly higher incidence of increased ICP values. The outcome in these patients was worse than in the nimodipine-treated patients.
Adverse Events
Adverse events were reported in 122 of the patients treated with nimodipine and in 113 patients in the pla- (Table 9) . Hypotensive events occurred in 71 patients in the nimodipine group and in 47 in the placebo group. Nimodipine treatment resulted in a somewhat larger drop in both systolic and mean blood pressure during the first 4 days after the start of treatment compared with placebo treatment, but this difference was not statistically significant. Furthermore, patients in the nimodipine group who suffered hypotension had an unfavorable outcome less often than patients noted to be hypotensive during placebo treatment. The numbers of patients with changes in serum concentrations of liver and pancreatic enzymes did not differ between the two groups.
Discussion
Effect of Nimodipine
The first randomized trial of nimodipine in headinjured patients (HIT 1) suggested that nimodipine might have a clinically useful, modest, beneficial effect, and the authors concluded that "there is need for further studies involving a larger number of patients. ''2 The trial reported in this paper fulfills this need, showing no significant effect of the administration of nimodipine in severe head injury. Indeed, the difference between the treated and control groups is less in this study than in the first. Nevertheless, the study has also raised the possibility that nimodipine may be beneficial in a specific type of head injury, as will be discussed below. The aim of the study was to detect or exclude, with a high degree of confidence, a 10% improvement in favorable outcome with nimodipine treatment. The relative improvement observed in this study was only 2%. The odds ratio of unfavorable outcome was 0.96, with a 95% confidence interval ranging from 0.72 to 1.26.
There is no consensus about the extent of improvement that would be clinically important in the treatment of severe head injury. In conditions that are extremely common and for a treatment that is inexpensive, improvements in outcome in even a small percent more patients may be worthwhile. However, the findings of this study make it highly unlikely that there is even a 5% overall improvement in the outcome of headinjured patients given nimodipine.
The lack of effect could be due to various factors, including the inappropriate timing of administration or dosage, or the presence of adverse side effects counteracting any beneficial effects. Experimentally, the clearest evidence of a beneficial effect of nimodipine was derived from studies in which treatment was initiated prior to the insult, 2z32 clearly not feasible in head-injured patients. Nevertheless, it is likely that early administration may be important in clinical efficacy of "neuroprotective" treatment. Recent studies show that evidence of reduced CBF is most often found when measurements are made within 4 or 8 hours after injury? .4 Furthermore, when tre~tting patients with spinal cord injury, a beneficial effect was observed only when methylprednisolone therapy was initiated within 8 hours of injury? ,~
In the previous trial of nimodipine in head injury (HIT 1), 2 treatment was commenced within 4 hours of injury in 21% of cases and within 8 hours in 49%; in the present study treatment was commenced within 4 hours in 10.4% of cases and within 8 hours in 49.5%. There was no suggestion in either study that the time after injury or after the patient was unable to obey commands influenced outcome. Therefore, it is unlikely that the lack of overall effect was because patients did not receive treatment sufficiently soon after the injury.
The systemic effects often observed in nimodipinetreated patients make it unlikely that the dose administered was insufficient to affect cerebral circulation. There was a slight overall reduction in systolic blood pressure, and hypotension was more frequently observed in patients receiving nimodipine. However, it is unlikely that hypotension caused adverse effects in nimodipine-treated patients. Thus, the occurrence of hypotension in nirnodipine-treated patients was associated with a less unfavorable outcome than that observed when hypotension occurred in control patients, but this difference did not reach statistical significance.
Comparison of Nimodipine Trials
The design of this trial, HIT 2, deliberately followed that of the first nimodipine trial, HIT 1, in most respects. 2 The main difference was that, whereas in HIT 1 entry was allowed up to 24 hours following injury, in HIT 2 entry was required within 12 hours from the time the patient was unable to obey commands and within 24 hours after injury. This change reflected the possibility that early administration might be more effective but, as noted above, neither study shows strong evidence in favor of an interrelationship between onset of nimodipine administration and efficacy.
It was possible to make a clinical assessment of the majority of patients in the HIT 1 trial at the time of entry into the study because, at that stage, only 38% were paralyzed and had undergone ventilation. By contrast, in the present study 21% of patients had undergone ventilation at the time of admission to the first hospital and 78% on entry into the trial. This limits comparison of responsiveness, in particular motor responses. However, a greater proportion of patients in the present study (81%) had at least one pupil reacting at entry into the trial as compared with the patients in the HIT 1 trial (65%). This supports the view that the patients in the present study were less severely injured than those in HIT 1. The inclusion of more patients with a less severe injury in the present study is in keeping with the belief that benefits of treatment are more likely to be seen in such patients than in those in deep coma from the time of injury.
Computerized Tomography Findings
The findings on CT after head injury, in addition to being important in clinical diagnosis and management, are of great value in the classification of injury according to type and severity, particularly when clinical signs are lost through paralysis and ventilation. In the present study, a classification similar to that used by Marshall, et al.,2~ was used. The frequency of occurrence of the different patterns on CT was similar to that reported by Marshall, et al. Moreover, similar variations in outcome were seen between the different CT scan categories. On the other hand, the discrepancy found between the interpretations of investigators and those of the review committee highlights the inconsistencies that can arise as a result of difficulty in applying the CT classification to individual patients. The increasing dependence upon CT findings as a method of classifying type and severity of injury makes the development of a scale that is both valid and reliable a priority.
Overall Outcome and Brain Damage
The fact that the GOS focuses upon an overall assessment of independence has raised concerns that it does not distinguish between disability due to different types of brain damage, nor indeed between disability due to brain damage and disability resulting from other injuries such as spinal cord damage or major visceral or skeletal injury. This study provides the first systematic assessment of the contribution of different factors to outcome after severe head injury. The results confirm that, in the great majority of disabled survivors, the important factor is the severity of brain damage; in only 2,5% of patients was there a difference between the outcome due to brain damage and the overall outcome. Furthermore, there was no evidence of a preferential effect of nimodipine in either of these groups.
Variations Between Centers
The present study is the largest conducted so far involving randomized double-blind administration of a therapeutic agent in the acute stage of severe head injury. It involved more patients in more centers in more countries than any previous report of head injury. It has provided insight into the organization, conduct, and analysis of such multicenter studies and into the variations in neurosurgical practice in different European centers. The inclusion of so many centers lends "robustness" to the findings of the trial; the results are likely to be representative of the practices and methods of management considered to be conventional and widely accepted, at least within Europe and perhaps throughout the world. Restriction of a study to one or a few centers may be attractive vis-g~-vis achieving a consistent approach to treatment, but such a trial can fail to take into account the variations observed between centers.
One item in the management of severely head injured patients about which opinion is clearly divided is the use of ICP monitoring. This monitoring was employed only in 41% of patients in eight centers in the present study. This variation is noted on both sides of the Atlantic, as demonstrated by the study of Hariri, et al. 12 
Subarachnoid Hemorrhage
The most intriguing findings in the present study were in patients with traumatic SAH. One conclusion of the previous study of head injury treatment with nimodipine was that "future studies should also explore 9 the influence and type of severity of injury. ''2 In the present study, the CT scans of a substantial proportion of patients (33% according to investigators and the review committee) showed evidence of traumatic SAH. In accordance with previous reports, 7 such patients had a worse outcome. In the group of patients who received placebo, 60% of those with CT scans showing SAH had an unfavorable outcome as compared with 30% in the absence of SAH. Furthermore, as in previous studies, the adverse effect of SAIl was seen even when other indicators such as patient age, clinical state, and cause of injury were taken into account 9
Treatment with nimodipine appeared to minimize the adverse effects of SAH. In patients assessed by the investigators to have SAH, 44% of those treated with nimodipine had an unfavorable outcome compared with 61% of placebo-treated patients. In the assessment by the review committee, 51% of nimodipine-treated and 66% of control patients had an unfavorable outcome.
Vasospasm
Angiography after head injury showed that vasospasm may occur, and transcranial Doppler ultrasound studies demonstrated that, after a head injury, increased velocities occur consistent with vasospasm. 6,m,27,29,3~ It is tempting to speculate that nimodipine may have a beneficial effect on outcome through an action on traumatic vasospasm, and to invoke comparison with vasospasm after spontaneous SAIl. Nevertheless, it should be noted that improvement in outcome after spontaneous SAIl occurred without an effect on angiographic vasospasm, u How nimodipine might favorably influence outcome in patients with traumatic SAH remains uncertain.
Conclusions
The findings of the present study and the analogy with spontaneous SAH provide a logical basis for a further study, focusing on patients with CT evidence of traumatic SAH. It would be necessary in such a study to establish a reliable method of reporting and grading SAH; efforts to establish such a system are currently a matter of priority.
